title: [Sensitivity surveillance of streptococci isolates for several antibiotics in Gifu prefecture (2005-2007)].
abstract: We investigated the susceptibility to antibacterials of streptococci isolated from 8 medical facilities in Gifu prefecture between 2005 and 2007. Strains used in this study include 118 of Group A streptococci, 89 of Group B streptococci, and 58 of group G streptococci. For Group A streptococci, cefteram and imipenem gave the lowest MIC90 at 0.0078 microg/mL, followed by cefditoren and cefcapene at 0.0156 microg/mL and penicillin G, amoxicillin and meropenem at 0.0313 microg/mL. For Group B streptococci, cefteram, cefditoren, cefcapene and imipenem gave the lowest MIC90 at 0.0313 microg/mL, followed by penicillin G and meropenem at 0.0625 microg/mL and amoxicillin at 0.125 microg/mL. For Group G streptococci, cefteram and imipenem gave the lowest MIC90 at 0.0078 microg/mL, followed by penicillin G, cefditoren, cefcapene and meropenem at 0.0156 microg/mL and amoxicillin at 0.0313 microg/mL. With Group A and B streptococci, the susceptibility data obtained in this study were compared with those of strains between 2000 and 2001. As for group A streptococci, the MIC50 and MIC90 of beta-lactam agents were about the same as those of previous study, however the MIC90 of quinolones increased about 2.5-fold and resistant strains were found. As for Group B streptococci, the MIC50 and MIC90 of almost all of the antibacterials were about the same as those of the previous study, however the MIC90 of clarithromycin increased about 10-fold, indicating that the resistant strains are widely spread.
authors.affiliation: Research Laboratories of Toyama Chemical Co., Ltd.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kawamoto
authors.forename: Nobuhiko
authors.initials: N
authors.lastname: Nomura
authors.forename: Junichi
authors.initials: J
authors.lastname: Mitsuyama
authors.forename: Kazukiyo
authors.initials: K
authors.lastname: Yamaoka
authors.forename: Yuko
authors.initials: Y
authors.lastname: Asano
authors.forename: Haruki
authors.initials: H
authors.lastname: Sawamura
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Suematsu
authors.forename: Mayumi
authors.initials: M
authors.lastname: Teraji
authors.forename: Hikonori
authors.initials: H
authors.lastname: Hashido
authors.forename: Yoko
authors.initials: Y
authors.lastname: Matsukawa
authors.forename: Shigenori
authors.initials: S
authors.lastname: Matsubara
authors.forename: Takanori
authors.initials: T
authors.lastname: Miyabe
authors.forename: Hiroshige
authors.initials: H
authors.lastname: Mikamo
authors.forename: Kunitomo
authors.initials: K
authors.lastname: Watanabe
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D024881:Drug Resistance, Bacterial; D006801:Humans; D007564:Japan; D013291:Streptococcus / Q000187:drug effects* / Q000302:isolation & purification; D013997:Time Factors
chemical_list: D000900:Anti-Bacterial Agents